UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 213,633 Shares of Danaher Corporation $DHR

by · The Cerbat Gem

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC cut its holdings in Danaher Corporation (NYSE:DHR – Free Report) by 4.1% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 5,012,228 shares of the conglomerate’s stock after selling 213,633 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.71% of Danaher worth $954,729,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. EP Wealth Advisors LLC acquired a new stake in Danaher in the second quarter valued at $3,807,000. Northwestern Mutual Wealth Management Co. increased its holdings in shares of Danaher by 303.7% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 248,020 shares of the conglomerate’s stock worth $56,777,000 after acquiring an additional 186,584 shares during the last quarter. Puzo Michael J acquired a new stake in Danaher during the 2nd quarter valued at $8,624,000. Madison Asset Management LLC acquired a new stake in shares of Danaher during the 2nd quarter worth about $85,451,000. Finally, Legal & General Group Plc boosted its holdings in shares of Danaher by 1.0% during the 4th quarter. Legal & General Group Plc now owns 4,495,287 shares of the conglomerate’s stock worth $1,029,061,000 after buying an additional 43,169 shares during the period. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher Trading Up 0.3%

NYSE:DHR opened at $216.41 on Friday. Danaher Corporation has a 12 month low of $160.93 and a 12 month high of $242.80. The company has a current ratio of 1.65, a quick ratio of 1.25 and a debt-to-equity ratio of 0.48. The stock has a market capitalization of $152.13 billion, a price-to-earnings ratio of 38.44, a PEG ratio of 2.69 and a beta of 0.78. The firm has a fifty day simple moving average of $199.46 and a two-hundred day simple moving average of $192.52.

Danaher (NYSE:DHR – Get Free Report) last released its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.85 by $0.09. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The company had revenue of $6.26 billion for the quarter, compared to analysts’ expectations of $6.12 billion. During the same quarter in the prior year, the firm earned $0.77 EPS. The business’s revenue was up 5.5% on a year-over-year basis. Analysts expect that Danaher Corporation will post 8.53 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

DHR has been the subject of several recent research reports. DZ Bank initiated coverage on Danaher in a research note on Wednesday, June 3rd. They issued a “buy” rating and a $210.00 price target for the company. Evercore reiterated an “outperform” rating and issued a $230.00 price objective on shares of Danaher in a research note on Monday, July 6th. Wells Fargo & Company cut their target price on Danaher from $212.00 to $195.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 22nd. Wolfe Research downgraded Danaher from an “outperform” rating to a “peer perform” rating in a research note on Monday, June 1st. Finally, Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a $240.00 target price on shares of Danaher in a research note on Wednesday, July 22nd. One analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $228.91.

View Our Latest Analysis on Danaher

About Danaher

(Free Report)

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.

Recommended Stories

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR – Free Report).